title: New targets in pediatric Acute Myeloid Leukemia.
abstract: In the last few years the improvements of chemotherapy regimens and supportive care has progressively ameliorated the prognosis of children suffering from Acute Myeloid Leukemia (AML). However, a still high percentage of children do not respond to first line treatments or relapse and need to undergo further treatments. The need to explore new agents other than chemotherapy has been highlighted in the last years in order to overcome drug related resistance and toxicity. Recently, novel therapies have been studied within early phases pediatric trials and seem to show encouraging results. In fact, the knowledge of molecular abnormalities related to AML pathogenesis has permitted to identify selective drugs that may represent an important tool for the development of patient-tailored treatments. Nowadays, FLT3, Aurora Kinases, mTORS's and proteasome inhibitors represents the most promising drugs that are being used in pediatric AML studies.
authors.affiliation: Clinical and Experimental Haematology Unit, G. Gaslini Institute, Genoa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Miano
authors.forename: C
authors.initials: C
authors.lastname: Micalizzi
authors.forename: M
authors.initials: M
authors.lastname: Calvillo
authors.forename: C
authors.initials: C
authors.lastname: Dufour
mesh_terms: D064096:Aurora Kinase A / Q000378:metabolism; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000639:trends*; D057285:Precision Medicine; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D051941:fms-Like Tyrosine Kinase 3 / Q000378:metabolism
chemical_list: C546842:MTOR protein, human; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; C576917:AURKA protein, human; D064096:Aurora Kinase A; D058570:TOR Serine-Threonine Kinases; D046988:Proteasome Endopeptidase Complex
keywords: Acute Myelod Leukemia; Children; Therapeutic advances